Physician profile
David Eghigian
NPI 1467459057
$362.44
in general payments reported to CMS, 2019-2025
12 companies · $18.52 in 2025
The $18.52 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.56 · 2021: $45.95 · 2022: $114 · 2023: $77.04 · 2024: $73.35 · 2025: $18.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $80.70 | 2022-2023 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.81 | 2019-2021 | |
| Lombart Brothers, INC. | $47.90 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $43.79 | 2024 | Xdemvy |
| Abbvie INC. | $32.00 | 2023 | Durysta |
| Sun Pharmaceutical Industries INC. | $18.52 | 2025 | |
| Shire North American Group INC | $17.47 | 2019 | |
| Alcon Vision LLC | $16.38 | 2024 | Total30 |
| Oyster Point Pharma, INC. | $15.29 | 2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $15.17 | 2023 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $13.23 | 2021 | |
| Amgen INC. | $13.18 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eghigian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.